Clinical trials: Capecitabine
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Chemotherapy, Breast Cancer, Metastatic
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature.
- Trial name
- NCT01067989
- Testing
- Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- HaEmek Medical Center, Israel
Gastric Cancer
Feasibility Study of Intraperitoneal Paclitaxel
This is a single arm phase 2 trial evaluating the efficacy and tolerability of intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer patients with peritoneal metastasis and/or cancer cells on…
- Trial name
- NCT01739894
- Testing
- IP Paclitaxel
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Hand-foot Syndrome
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated.
- Trial name
- NCT01609166
- Testing
- Allopurinol
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Adenocarcinoma
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
The primary aim of this dose-finding study is to determine the maximum tolerated dose of taxotere, eloxatin and capecitabine (TEX) in combination with herceptin given every third week as first-line treatment in patients with…
- Trial name
- NCT01295086
- Testing
- Docetaxel, Oxaliplatin, Capecitabine
- Where
- 4 sites in Denmark
- Volunteers
- 27 people
- Sponsor
- Odense University Hospital
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Biology Guided Therapy for Breast Cancer for ER Positive
There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- SPOCK (NCT04965688)
- Testing
- Biopsy-Guided Therapy Selection
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Elderly Metastatic Colorectal Cancer Patients
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Oxaliplatin-based doublets plus bevacizumab are standard first-line therapy options for patients (pts) with metastatic colorectal cancer (mCRC).
- Trial name
- COBRA (NCT03451370)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Breast Cancer
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Primarily, this clinical investigation compares the rates (percentages) of pathological complete remissions attained at the time of final surgery following 6 cycles each of epirubicin + docetaxel + capecitabine-containing…
- Trial name
- NCT00309556
- Testing
- Epirubicin, Docetaxel, Capecitabine
- Where
- 26 sites in Austria
- Volunteers
- 536 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Colorectal Neoplasms, Peritoneal Neoplasms
Adjuvant HIPEC in High Risk Colon Cancer
This study aims to determine the oncological effectiveness of adjuvant HIPEC, using intraperitoneal oxaliplatin with concomitant i.v.
- Trial name
- COLOPEC (NCT02231086)
- Testing
- Adjuvant HIPEC (open/laparoscopic), Standard adjuvant systemic chemotherapy, Diagnostic laparoscopy
- Where
- 9 sites in Netherlands
- Volunteers
- 204 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Biliary Tract Cancer
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth…
- Trial name
- TreeTopp (NCT03093870)
- Testing
- Varlitinib, Capecitabine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- ASLAN Pharmaceuticals
Locally Advanced or Metastatic Breast Cancer
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally…
- Trial name
- NCT07461454
- Testing
- YL202, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Adenocarcinoma of the Rectum
Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
Bowel cancer is the second most common tumour with 41 000 new cases diagnosed annually in the UK, 447 000 across Europe and 1.36 million worldwide; of which one third are located in the rectum.
- Trial name
- STAR-TREC (NCT02945566)
- Testing
- Standard TME surgery, Long course concurrent chemoradiation with capecitabine and radiotherapy, Short course radiotherapy
- Where
- 5 sites in Belgium, Denmark and 3 more
- Volunteers
- 380 people
- Sponsor
- University of Birmingham
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
Capecitabine is recommended for adjuvant treatment of advanced or metastatic breast cancer and is particularly effective in patients with triple-negative breast cancer (TNBC).
- Trial name
- CALORIE (NCT03821454)
- Testing
- Capecitabine
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Colon Cancer, Surgery
The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer
The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing.
- Trial name
- NCT04416854
- Testing
- resection of primary tumor, XELOX, mFOLFOX6
- Where
- China
- Volunteers
- 627 people
- Sponsor
- Fudan University
Locally Advanced Unresectable Gastric Cancer, Metastatic Gastric Cancer
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
This is a randomized, parallel group, non-blinded phase III trial. Patients with advanced (locoregional or metastatic) gastric cancer not previously treated with chemotherapy for this stage will be randomized in a 1:1 ratio to…
- Trial name
- NCT02076594
- Testing
- Docetaxel, Epirubicin, Oxaliplatin
- Where
- 25 sites in Italy
- Volunteers
- 171 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in…
- Trial name
- NCT06760520
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer, Gastroesophageal Cancer
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in…
- Trial name
- GASTRANOX (NCT00718354)
- Testing
- Enoxaparin, Standard Chemotherapy
- Where
- 15 sites in India
- Volunteers
- 740 people
- Sponsor
- Thrombosis Research Institute
Advanced Gastric Cancer, Peritoneal Carcinomatosis
A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination
Advanced gastric cancer combined with peritoneal seeind has dismal prognosis with poor response to systemic chemotherapy and with rapid aggravation of symptoms such as abdominal pain, ileus, and poor nutritional intake.
- Trial name
- NCT04797923
- Testing
- 1. Treatment: IP chemotherapy + Systemic chemotherapy, 2. Response evaluation after 4 cycles of IP + systemic chemotherapy
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Gangnam Severance Hospital
Metastatic Pancreatic Adenocarcinoma
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma
Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC) is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin).
- Trial name
- ALIX (NCT03974854)
- Testing
- XELOXIRI-3, Gemcitabine
- Where
- 5 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon